PMID- 29063487
OWN - NLM
STAT- MEDLINE
DCOM- 20180808
LR  - 20181113
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 26
IP  - 1
DP  - 2018 Feb
TI  - Targeting of circulating Th17 cells by beta-D-mannuronic acid (M2000) as a novel 
      medication in patients with rheumatoid arthritis.
PG  - 57-65
LID - 10.1007/s10787-017-0410-8 [doi]
AB  - OBJECTIVE: This study aimed at investigating the inhibitory effect of 
      beta-D-mannuronic acid (M2000) on the Th17 circulating levels and IL-17 a related 
      cytokine in rheumatoid arthritis (RA) patients. METHODS: The study included 27 
      patients with RA who had failed response to treatment. All patients were treated 
      orally by M2000 at a dose of 500 mg twice daily for 12 weeks (Clinical trial 
      identifier: IRCT2014011213739N2). The patients based on anti-tumor necrosis 
      factor alpha (TNFalpha) blocker treatment were classified into two groups 
      (conventional group and etanercept group). They were then allowed to continue 
      their treatment excluding non-steroidal anti-inflammatory drugs (NSAIDs). The 
      frequency of circulating Th17 cells and IL-17 serum level were determined before 
      and 12 weeks after M2000 therapy and were compared to the healthy controls by 
      using flow cytometry analysis and ELISA method, respectively. RESULTS: At 
      baseline, higher circulating Th17 and IL-17 serum levels were significantly 
      observed in both groups of RA patients than in the healthy controls (all 
      P < 0.001). The frequency of Th17 cells significantly decreased in the 
      conventional group as well as in the etanercept group after M2000 therapy but the 
      level of reduction was higher in the conventional group compared to the 
      etanercept group (P < 0.03 and P < 0.04, respectively). The IL-17 serum level 
      significantly decreased in both groups after M2000 therapy (P < 0.01 and 
      P < 0.02, respectively). Furthermore, the frequency of Th17 cells was positively 
      correlated with Disease Activity Score (DAS28) (r = 0.34, P = 0.02). CONCLUSION: 
      M2000 shows the inhibitory effect on the frequency of circulating Th17 cells as 
      well as in the production of IL-17 in RA patients.
FAU - Ahmadi, Hossein
AU  - Ahmadi H
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Box: 14155-6446, Tehran, Iran.
FAU - Mahmoudi, Mahdi
AU  - Mahmoudi M
AD  - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Gharibdoost, Farhad
AU  - Gharibdoost F
AD  - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Vojdanian, Mahdi
AU  - Vojdanian M
AD  - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Jamshidi, Ahmad Reza
AU  - Jamshidi AR
AD  - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Fattahi, Mohammad Javad
AU  - Fattahi MJ
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Box: 14155-6446, Tehran, Iran.
AD  - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
FAU - Aghazadeh, Zahra
AU  - Aghazadeh Z
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Box: 14155-6446, Tehran, Iran.
FAU - Barati, Anis
AU  - Barati A
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Box: 14155-6446, Tehran, Iran.
FAU - Mirshafiey, Abbas
AU  - Mirshafiey A
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Box: 14155-6446, Tehran, Iran. mirshafiey@tums.ac.ir.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20171023
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Hexuronic Acids)
RN  - 0 (Interleukin-17)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 980IT47Y34 (mannuronic acid)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/metabolism
MH  - Case-Control Studies
MH  - Cytokines/metabolism
MH  - Etanercept/therapeutic use
MH  - Female
MH  - Hexuronic Acids/*therapeutic use
MH  - Humans
MH  - Interleukin-17/blood
MH  - Male
MH  - Middle Aged
MH  - Th17 Cells/*drug effects/*metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - DMARD
OT  - IL-17
OT  - M2000
OT  - Mannuronic acid
OT  - Rheumatoid arthritis
OT  - Th17 cells
EDAT- 2017/10/25 06:00
MHDA- 2018/08/09 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/09/04 00:00 [received]
PHST- 2017/10/11 00:00 [accepted]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2018/08/09 06:00 [medline]
PHST- 2017/10/25 06:00 [entrez]
AID - 10.1007/s10787-017-0410-8 [pii]
AID - 10.1007/s10787-017-0410-8 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2018 Feb;26(1):57-65. doi: 10.1007/s10787-017-0410-8. Epub 
      2017 Oct 23.